（文章来源：证券日报） 证券日报网讯 9月2日晚间，毕得医药发布公告称，公司已于近日完成了营业执照的变更及修订后的 《公司章程》备案手续，并取得了由上海市市场监督管理局换发的《营业执照》。 ...

Group 1 - The company, Bid Pharma, announced plans to hold a collective performance briefing for the biopharmaceutical and CXO industry on September 15, 2025, from 15:00 to 17:00 [1]

证券代码：688073 证券简称：毕得医药 公告编号：2025-076 类型：股份有限公司（上市、自然人投资或控股） 法定代表人：戴岚 注册资本：人民币9088.2948万元整 上海毕得医药科技股份有限公司 成立日期：2007年04月27日 关于完成工商变更并取得营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）已于近日 完成了营业执照的变更及修订后的《公司章程》备案手续，并取得了 由上海市市场监督管理局换发的《营业执照》。具体登记信息如下： 名称：上海毕得医药科技股份有限公司 统一社会信用代码：91310110660715642B 化工产品销售（不含许可类化工产品）；信息咨询服务（不含许可类 信息咨询服务）；生物基材料技术研发；细胞技术研发和应用；工程 和技术研究和试验发展；第一类医疗器械销售；普通货物仓储服务（不 含危险化学品等需许可审批的项目）；专用化学产品制造（不含危险 化学品）；企业管理咨询；信息技术咨询服务；玻璃仪器销售；实验 分析仪器销售；仪器仪 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-075 上海毕得医药科技股份有限公司 关于召开 2025 年半年度科创板生物制品及 CXO 行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 08 日（星期一）至 09 月 12 日（星期五） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 ir@bidepharmatech.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 上海毕得医药科技股份有限公司（以下简称"毕得医药"或"公 司"）于 2025 年 8 月 22 日发布公司 2025 年半年度报告，为便于广大 投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况， 公司计划于 2025 年 09 月 15 日（星期一）15:00-17:00 举行 2025 年半 年度科创板生物制品及 CXO 行业集体业绩说明会，就投资者关心的 问题进行交流。 会议召开时间：2025 年 ...

Company Overview - Bid Pharma is located in Yangpu District, Shanghai, and was established on April 27, 2007. The company went public on October 11, 2022. Its main business focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1][2]. Financial Performance - For the first half of 2025, Bid Pharma achieved a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, showing a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Stock Performance - As of September 1, Bid Pharma's stock price increased by 2.34%, reaching 68.68 yuan per share, with a total market capitalization of 6.242 billion yuan. The stock has risen by 42.19% year-to-date, with a 2.25% increase over the last five trading days, 14.95% over the last 20 days, and 48.18% over the last 60 days [1]. - The stock's trading volume on September 1 was 61.0887 million yuan, with a turnover rate of 2.11% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 3,782, a rise of 4.76%. The average number of circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by China Europe Medical Health Mixed A and an increase by Agricultural Bank of China Medical Health Stock [3].

Market Overview - The medical services sector rose by 3.64% on August 29, with the leading stock being Puris [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Medical Services - Zenggansi (301257) closed at 43.54, up 20.01% with a trading volume of 64,900 shares and a turnover of 278 million [1] - Haoyuan Pharmaceutical (688131) closed at 68.48, up 13.70% with a trading volume of 189,200 shares and a turnover of 1.256 billion [1] - Bidai Pharmaceutical (688073) closed at 67.11, up 10.43% with a trading volume of 28,300 shares and a turnover of 182 million [1] - Meidi Xi (688202) closed at 64.21, up 8.96% with a trading volume of 124,400 shares and a turnover of 784 million [1] - WuXi AppTec (603259) closed at 103.30, up 7.95% with a trading volume of 1,016,600 shares and a turnover of 10.18 billion [1] Top Losers in Medical Services - Digital Human (835670) closed at 17.54, down 6.20% with a trading volume of 127,200 shares and a turnover of 227 million [2] - Puri Eye Hospital (301239) closed at 40.78, down 4.63% with a trading volume of 49,600 shares and a turnover of 203 million [2] - Yingkang Life (300143) closed at 10.64, down 3.45% with a trading volume of 230,300 shares and a turnover of 250 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 1.259 billion from institutional investors, while retail investors experienced a net outflow of 446 million [2][3] - Major stocks like WuXi AppTec had a net inflow of 1.269 billion from institutional investors, while it faced a net outflow of 741 million from retail investors [3]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Group 1 - Bid Pharma's stock price dropped by 5.4% to 59.18 CNY per share, with a trading volume of 51.32 million CNY and a turnover rate of 1.94%, resulting in a total market capitalization of 5.378 billion CNY [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Guodu Securities has one fund heavily invested in Bid Pharma, with Guodu Jucheng (011389) holding 7,000 shares, accounting for 3.98% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a total scale of 10.2022 million CNY, with a year-to-date return of 7.5% and a one-year return of 11.33% [2] - Since its inception, the fund has experienced a loss of 46.84% [2] Group 3 - The fund managers of Guodu Jucheng are Liao Xiaodong, Zhang Xiaolei, and Gong Yongjin, with varying tenures and performance records [3] - Liao Xiaodong has a tenure of 5 years and 107 days, with the best fund return of -24.14% and the worst return of -64.86% [3] - Zhang Xiaolei has a tenure of 6 years and 257 days, achieving a best return of 80.09% and a worst return of -23.6% [3] - Gong Yongjin has a tenure of 1 year and 148 days, with a consistent return of 7.03% [3]

Group 1 - On August 27, Bid Pharma executed a block trade of 143,000 shares, with a transaction value of 8.58 million yuan, accounting for 7.86% of the total trading volume for the day [1] - The transaction price was 60 yuan, representing a discount of 4.09% compared to the market closing price of 62.56 yuan [1] Group 2 - The block trade was facilitated by Haitong Securities, with both the buying and selling departments being the same [2]

Summary of Key Points Core Viewpoint - Bid Pharma experienced significant trading activity on August 25, with a total of 133,500 shares traded at a total value of 8.01 million yuan, reflecting a discount of 10.67% compared to the closing price of the day [2]. Trading Activity - The stock had three transactions on the block trading platform, all at a price of 60.00 yuan per share [2]. - Over the past three months, Bid Pharma has recorded four block trades totaling 10.11 million yuan [2]. Stock Performance - The closing price of Bid Pharma on the same day was 67.17 yuan, marking an increase of 4.11% [2]. - The stock's turnover rate for the day was 6.10%, with a total trading volume of 176 million yuan [2]. - There was a net outflow of 5.05 million yuan in main funds throughout the day, while the stock has seen a cumulative increase of 9.65% over the past five days, with a total net inflow of 3.79 million yuan [2]. Margin Trading Data - The latest margin financing balance for Bid Pharma stands at 45.40 million yuan, which has increased by 3.27 million yuan, representing a growth of 7.75% over the past five days [2].